Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has demonstrated remarkable efficacy in relapsed/refractory MM (RRMM). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.